melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-12. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
=== Origin, early development and migration to the thymus === All T cells originate from c-kit+Sca1+ haematopoietic stem cells (HSC) that reside in the bone marrow. In some cases, the origin might be the foetal liver during embryonic development. The HSC then differentiate into multipotent progenitors (MPP) which retain the potential to become both myeloid and lymphoid cells. The process of differentiation then proceeds to a common lymphoid progenitor (CLP), which can only differentiate into T, B, or NK cells. These CLP cells then migrate via the blood to the thymus, where they engraft. Henceforth they are known as thymocytes, the immature stage of a T cell. The earliest cells which arrived in the thymus are commonly termed double-negative, as they express neither the CD4 nor CD8 co-receptor. The newly arrived CLP cells are CD4−CD8−CD44+CD25−ckit+ cells, and are termed early thymic progenitor (ETP) cells. These cells will then undergo a round of division and downregulate c-kit and are termed double-negative one (DN1) cells. To become T cells, the thymocytes must undergo multiple DN stages as well as positive selection and negative selection. Double negative thymocytes can be identified by the surface expression of CD2, CD5, and CD7. Still during the double negative stages, CD34 expression stops and CD1 is expressed. Expression of both CD4 and CD8 makes them double positive, and matures into either CD4+ or CD8+ cells.
While deployments expanded, available data indicate a more restrained operational role, with fewer confrontations and seizures, alongside new duties such as infrastructure projects and vaccine distribution. Under U.S. pressure, the National Guard has been increasingly deployed to stem migrant flows from Central America.
During the fall of 1924, Marvel found him a job as an assistant biochemist at the Philadelphia General Hospital that helped him to teach clinical chemistry at the Graduate School of Medicine, University of Pennsylvania. Marvel would pay for the trip to Pennsylvania in exchange for du Vigneaud's preparation of 10 pounds of cupferron. Resuming his academic career in 1925, du Vigneaud joined the group of John R. Murlin at the University of Rochester for his PhD thesis. He graduated in 1927 with his work The Sulfur of Insulin. After a post-doctoral position with John Jacob Abel at Johns Hopkins University Medical School (1927–1928), he traveled to Europe as a National Research Council Fellow in 1928–1929, where he worked with Max Bergmann and Leonidas Zervas at the Kaiser Wilhelm Institute for Leather Research in Dresden, and with George Barger at the University of Edinburgh Medical School. He then returned to the University of Illinois as a professor. In 1932, he started working at the George Washington University Medical School in Washington, D.C., and in 1938, he attended the Cornell Medical College in New York City, where he stayed until his emeritation in 1967. Following retirement, he held a position at Cornell University in Ithaca, New York. In 1974, du Vigneaud had a stroke which forced his retirement. He died in 1978, one year after his wife's death in 1977.
Langer–Giedion syndrome is a very rare genetic disorder caused by a deletion of chromosomal material. Diagnosis is usually made at birth or in early childhood. The features associated with this condition include mild to moderate learning difficulties, short stature, unique facial features, small head and skeletal abnormalities including bony growths projecting from the surfaces of bones.
As of 2024, the legal status of ibogaine varies widely among countries, as it may be illegal to possess or use, may be legalized, may be decriminalized, or is under consideration for future legislation. In the United States, although some cities and states have decriminalized psychedelic chemicals, plants and mushrooms, ibogaine has had minimal legislation, and remains illegal under federal law, as of 2026. The US Drug Enforcement Administration enforces ibogaine as a Schedule I substance under the Controlled Substances Act. A 2026 executive order in the US accelerates ibogaine research, regulatory review, patient access through Right to Try, and potential rescheduling if clinical trials and FDA approval criteria are successful. In March 2026, Texas announced plans to use $50 million approved by the Texas Legislature the previous year to create its own ibogaine research program after several proposals from drug companies failed to meet requirements for partnering with the state.
Sources: en.wikipedia.org
==== Tax deductible for loan interest for U.S.-assembled cars ==== The law allows individuals to deduct up to $10,000 per year in auto loan interest for new cars that had their final assembly in the United States and were purchased between January 1, 2025, and December 31, 2028. The vehicle must be for personal use, rather than business use. It must be a car, minivan, van, sport utility vehicle, pickup truck, or motorcycle with a gross vehicle weight rating of less than 14,000 pounds. All-terrain vehicles, trailers, campers, used vehicles, and leased vehicles are not eligible. The vehicle's Automobile Information Disclosure label must show that the place of its final assembly was the United States. The maximum tax deduction is reduced out for individuals whose modified adjusted gross income is greater than $100,000 (or $200,000 for married couples filing jointly), and it is eliminated for individuals whose modified adjusted gross income is greater than $150,000 (or $250,000 if married filing jointly). A taxpayer is not required to itemize their tax deductions in order to take the tax deduction. From 2025 to 2028, auto loan lenders are required to report loan details to the Internal Revenue Service if they receive at least $600 of interest on qualifying vehicle loans.
== Background == By the mid-1790s, Humboldt had devoted himself wholly to scientific investigations. Despite being offered a promotion and an increase in pay, he resigned his position as a mining official in the Prussian civil service in order to embark on a journey that would “advance him scientifically.” To the Minister of Mines in Berlin Humboldt declared: "I am considering a complete change in my mode of life, and I intend to withdraw from any official position with the state." His health, he claimed, had suffered. All he had wanted was to prepare himself for a scientific expedition by a practical employment in the mines. "As I have a deep conviction that such an expedition is highly important for increasing our knowledge of geology and physical science, I am exceedingly eager to devote my energies immediately to this end. After his mother's death in 1796, Humboldt inherited the financial means to pursue independent explorations. He decided to go to Italy, where he wanted to spend a year to a year and a half researching volcanoes. From there, he wanted to travel via Paris to England, where he would board a ship to the West Indies. However, the political instability caused by Napoleon's Italian campaign in 1797 forced Humboldt to cancel his plans. In May 1798, Humboldt traveled to Paris, where he met the botanist Aimé Bonpland. After their attempt to travel to Egypt had once again failed due to Napoleon and his campaign there, the two decided to go to Madrid in December 1798.
coli, but intestinal macrophages still do not release cytokines, even after phagocytosis. Also, intestinal macrophages do not express lipopolysaccharide (LPS), IgA, or IgG receptors. The lack of LPS receptors is important for the gut as the intestinal macrophages do not detect the microbe-associated molecular patterns (MAMPS/PAMPS) of the intestinal microbiome. Nor do they express IL-2 and IL-3 growth factor receptors.
== Biological function == Lipoic acid is a cofactor for five enzymes or classes of enzymes: pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, the glycine cleavage system, branched-chain alpha-keto acid dehydrogenase, and the α-oxo(keto)adipate dehydrogenase. The first two are critical to the citric acid cycle. The GCS regulates glycine concentrations. HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are targets of the reduced form (open dithiol) of (R)-lipoic acid.
Sources: en.wikipedia.org
=== Engineering strain === Engineering strain, also known as Cauchy strain, is expressed as the ratio of total deformation to the initial dimension of the material body on which forces are applied. In the case of a material line element or fiber axially loaded, its elongation gives rise to an engineering normal strain or engineering extensional strain e, which equals the relative elongation or the change in length ΔL per unit of the original length L of the line element or fibers (in meters per meter). The normal strain is positive if the material fibers are stretched and negative if they are compressed. Thus, we have
== Lithium-titanate battery == The lithium-titanate battery is a rechargeable battery that is much faster to charge than other lithium-ion batteries. It differs from other lithium-ion batteries because it uses lithium-titanate on the anode surface rather than carbon. This is advantageous because it does not create a solid electrolyte interface layer, which acts as a barrier to the ingress and egress of Li-ion to and from the anode. This allows lithium-titanate batteries to be recharged more quickly and provide higher currents when necessary. A disadvantage of the lithium-titanate battery is a much lower capacity and voltage than the conventional lithium-ion battery. The lithium-titanate battery is currently being used in battery electric vehicles and other specialist applications.
== Symptoms == Cats will generally show a gradual onset of the disease over a few weeks or months, and it may escape notice for even longer. The first outward symptoms are sudden weight loss (or occasionally gain) accompanied by polydipsia and polyuria. Polyphagia or anorexia may be observed. Neuropathy in the hind legs may cause the cat to develop a plantigrade stance, walking on its hocks rather than its toes. The front legs may develop a corresponding palmigrade stance, with the cat standing on its "palms" rather than its toes. A fasting glucose blood test will normally be suggestive of diabetes at this point. The same home blood test monitors used in humans are also used on cats, usually by obtaining blood from the ear edges or paw pads. As the disease progresses, ketone bodies will be present in the urine, which can be detected with the same urine strips used for testing human urine. In the final stages, the cat starts wasting, with the body breaking down its own fat and muscle to survive. Lethargy/limpness and acetone-smelling breath are acute symptoms of ketoacidosis and/or dehydration and constitute a medical emergency. Untreated, diabetes leads to coma and then death.
Actin networks give mechanical support to cells and provide trafficking routes through the cytoplasm to aid signal transduction. Rapid assembly and disassembly of actin network enables cells to migrate. Actin is extremely abundant in most cells, comprising 1–5% of the total protein mass of most cells, and 10% of muscle cells. The actin protein is found in both the cytoplasm and the cell nucleus. Its location is regulated by cell membrane signal transduction pathways that integrate the stimuli that a cell receives stimulating the restructuring of the actin networks in response. The role of actin as a regulator of chemical processes in the cell cytoplasm was proposed. The cytoplasm is viscous, crowded, and heterogeneous, a dynamic complex, a gel-like substance that restricts free diffusion but is capable of managing a myriad of reactions at any moment. The high capacity of the cytoplasm to perform complex chemical reactions can be explained by a two-phase system of organization, in which catalytic complexes are immobilized in the elastic solid phase (cytomatrix), thereby overcoming spatial hindrances and crowding. Nutrients and substrates can be delivered by liquid-phase (cytosol) flux, and the motor protein actin provides the driving force for cytomatrix mechanics. Approximately 150 actin-binding and regulatory proteins fine-tune metabolic processes in the cytoplasm, thereby overcoming cytoplasmic viscosity. The energy source for actin dynamics in normal physiological conditions is mitochondria.
===== Reverse transcription ===== One way of doing this is to develop nucleotide or nucleoside analogues that look like the building blocks of RNA or DNA, but deactivate the enzymes that synthesize the RNA or DNA once the analogue is incorporated. This approach is more commonly associated with the inhibition of reverse transcriptase (RNA to DNA) than with "normal" transcriptase (DNA to RNA). The first successful antiviral, aciclovir, is a nucleoside analogue, and is effective against herpesvirus infections. The first antiviral drug to be approved for treating HIV, zidovudine (AZT), is also a nucleoside analogue. An improved knowledge of the action of reverse transcriptase has led to better nucleoside analogues to treat HIV infections. One of these drugs, lamivudine, has been approved to treat hepatitis B, which uses reverse transcriptase as part of its replication process. Researchers have gone further and developed inhibitors that do not look like nucleosides, but can still block reverse transcriptase. Another target being considered for HIV antivirals include RNase H—which is a component of reverse transcriptase that splits the synthesized DNA from the original viral RNA.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.